Comparison of Efficacy of Roxadustat and Erythropoietin for the Treatment of Renal Anemia in Patients with Chronic Kidney Disease
DOI:
https://doi.org/10.51985/Keywords:
Roxadustat, erythropoietin, renal anemia, chronic kidney disease, hemodialysisAbstract
Objective: To compare the effectiveness of roxadustat and erythropoietin in the treatment of renal anemia in the chronic kidney disease patients under hemodialysis.
Study design & settings: This was a non-randomized quasi-experimental comparative study conducted in the Department of Nephrology, Allied Hospital, Faisalabad.
Methodology: Non-probability consecutive sampling was used to enroll 490 adults with chronic kidney disease, renal anemia, and maintenance hemodialysis. Treatment assignment was non-randomized; no random sequence generation or allocation concealment was used. Participants received either oral roxadustat (Group A) or subcutaneous recombinant human erythropoietin (Group B) according to the treating unit’s prescribed anemia-management regimen. Hemoglobin was assessed at baseline and during follow-up, with the prespecified primary efficacy endpoint defined as achievement of hemoglobin 10–12 g/dL at 12 weeks.
Results: There were 245 participants in each treatment group. Mean hemoglobin increased from 8.7±0.8 g/dL at baseline to 11.1±0.9 g/dL at 12 weeks in the roxadustat group and from 8.6±0.7 g/dL to 10.7±1.0 g/dL in the erythropoietin group. The primary efficacy endpoint was achieved by 149/245 (60.8%) participants receiving roxadustat and 121/245 (49.4%) receiving erythropoietin (p=0.011). The absolute risk difference was 11.4% (95% CI 2.7%–20.2%), the relative risk was 1.23 (95% CI 1.05–1.45), and the odds ratio was 1.59 (95% CI 1.11–2.28).
Conclusion: In this non-randomized quasi-experimental study, achievement of the target hemoglobin range at 12 weeks was more frequent in the roxadustat group than in the erythropoietin group
Downloads
References
1. Akizawa T, Iwasaki M, Yamaguchi Y, Majikawa Y, Reusch
M. Phase 3, randomized, double-blind, active-comparator
study of oral roxadustat in CKD patients with anemia on
hemodialysis in Japan. J Am Soc Nephrol. 2020;31(7):1628-
1639. doi:10.1681/ASN.2019060623.
2. Wang L, Yin H, Yang L, Zhang F, Wang S, Liao D. The
efficacy and safety of roxadustat for anemia in patients with
chronic kidney disease: a meta-analysis. Front Pharmacol.
2022;13:779694. doi:10.3389/fphar.2022.779694.
3. Hirai K, Nonaka H, Ueda M, Kato A, Nakayama M, Yoshida
T, et al. Effects of roxadustat on the anemia and iron
metabolism of patients undergoing peritoneal dialysis. Front
Med (Lausanne). 2021;8:667117. doi:10.3389/ fmed.2021.
667117.
4. Liu J, Yang F, Waheed Y, Li S, Liu K, Zhou X. The role of
roxadustat in chronic kidney disease patients complicated
with anemia. Korean J Intern Med. 2023;38(2):147-156.
doi:10.3904/kjim.2022.180.
5. Barratt J, Andric B, Tataradze A, Schömig M, Reusch M,
Valluri U, et al. Roxadustat for the treatment of anaemia in
chronic kidney disease patients not on dialysis: a phase 3,
randomized, open-label, active-controlled study. Nephrol Dial
Transplant. 2021;36(9):1616-1628. doi:10.1093/ndt/gfab191
6. Choukroun G, Strutz F, Harkavyi A, Santos V, Jiletcovici A,
Del Vecchio L. Efficacy and safety of roxadustat in patients
with CKD: pooled analysis by baseline inflammation status.
J Clin Med. 2025;14(2):303. doi:10.3390/jcm14020303.
7. Jin C, Zhang Y, Luo C, Ren Y, Ye B, Hu X, et al. Comparison
of efficacy of roxadustat and erythropoietin for the treatment
of renal anemia in patients with chronic kidney disease: a
retrospective study. Transl Androl Urol. 2022;11(11):1568-
1578. doi:10.21037/tau-22-690.
8. Fishbane S, Pollock CA, El-Shahawy M, Escudero ET, Rastogi
A, Van BP, et al. Roxadustat versus epoetin alfa for treating
anemia in patients with chronic kidney disease on dialysis.
Kidney Int Rep. 2022;7(4):850-860. doi:10.1016/j.ekir.2022.
01.1026.
9. Fishbane S, El-Shahawy MA, Pecoits-Filho R, Van BP, Houser
MT, Frison L, et al. Roxadustat for treating anemia in patients
with CKD not on dialysis: results from a randomized phase
3 study. J Am Soc Nephrol. 2021;32(3):737-755. doi:10.1681/
ASN.2020081150.
10. Stoumpos S, Jardine AG, Mark PB. Hypoxia-inducible factor
prolyl hydroxylase inhibitors for anaemia of chronic kidney
disease: current evidence and future directions. Lancet.
2024;403(10436):1827-1841. doi:10.1016/S0140-6736(24)
00366-4.
11. Jin C, Zhang Y, Luo C, Ren Y, Ye B, Hu X, et al. Comparison
of efficacy of roxadustat and erythropoietin for the treatment
of renal anemia in patients with chronic kidney disease: a
retrospective study. Transl Androl Urol. 2022;11(11):1568-
1578. doi:10.21037/tau-22-690.
12. Fishbane S, Pollock CA, El-Shahawy M, Escudero ET, Rastogi
A, Van BP, et al. Roxadustat versus epoetin alfa for treating
anemia in patients with chronic kidney disease on dialysis.
Kidney Int Rep. 2022;7(4):850-860. doi:10.1016/j.ekir.2022
.01.1026.
13. Akizawa T, Iwasaki M, Yamaguchi Y, Majikawa Y, Reusch
M. Phase 3, randomized, double-blind, active-comparator
study of oral roxadustat in CKD patients with anemia on
hemodialysis in Japan. J Am Soc Nephrol. 2020;31(7):1628-
1639. doi:10.1681/ASN.2019060623.
14. Barratt J, Andric B, Tataradze A, Schömig M, Reusch M,
Valluri U, et al. Roxadustat for the treatment of anaemia in
chronic kidney disease patients not on dialysis: a phase 3,
randomized, open-label, active-controlled study. Nephrol Dial
Transplant. 2021;36(9):1616-1628. doi:10.1093/ndt/gfab191.
15. Wang L, Yin H, Yang L, Zhang F, Wang S, Liao D. The
efficacy and safety of roxadustat for anemia in patients with
chronic kidney disease: a meta-analysis. Front Pharmacol.
2022;13:779694. doi:10.3389/fphar.2022.779694.
16. Zhou Q, Wang D, Li H, Wang Y, Liu X, Zhang Y, et al. The
efficacy and safety of roxadustat for anemia in patients with
dialysis-dependent chronic kidney disease: a systematic review
and meta-analysis. Ren Fail. 2023;45(1):2195011.
doi:10.1080/0886022X.2023.2195011.
17. Liu J, Yang F, Waheed Y, Li S, Liu K, Zhou X. The role of
roxadustat in chronic kidney disease patients complicated
with anemia. Korean J Intern Med. 2023;38(2):147-156.
doi:10.3904/kjim.2022.180.
18. Stoumpos S, Jardine AG, Mark PB. Hypoxia-inducible factor
prolyl hydroxylase inhibitors for anaemia of chronic kidney
disease: current evidence and future directions. Lancet.
2024;403(10436):1827-1841. doi:10.1016/S0140-6736(24)
00366-4.
19. Tian L, Li Y, Zhang X, Wang L, Chen Y, Zhao J, et al.
Cardiovascular and renal safety outcomes of roxadustat in
chronic kidney disease patients with anemia: a systematic
review and meta-analysis. Front Pharmacol. 2024;15:1338731.
doi:10.3389/fphar.2024.1338731.
20. Li X, Zhang Y, Liu H, Chen J, Wang F, Zhou Y, et al.
Assessment of the safety of roxadustat for cardiovascular
outcomes in patients with chronic kidney disease anemia: a
systematic review and meta-analysis. BMC Nephrol.
2024;25:238. doi:10.1186/s12882-024-03649-0.
21. Zhang L, Zhang Y, Wang C, Luo X, Li X, Sun H, et al. Effect
of roxadustat versus erythropoietin for treating renal anemia
in patients with diabetic kidney disease. Ann Transl Med.
2022;10(23):1282. doi:10.21037/atm-22-4344.
22. Choukroun G, Strutz F, Harkavyi A, Santos V, Jiletcovici A,
Del Vecchio L. Efficacy and safety of roxadustat in patients
with CKD: pooled analysis by baseline inflammation status.
J Clin Med. 2025;14(2):303. doi:10.3390/jcm14020303.
23. Hirai K, Nonaka H, Ueda M, Kato A, Nakayama M, Yoshida
T, et al. Effects of roxadustat on the anemia and iron
metabolism of patients undergoing peritoneal dialysis. Front
Med (Lausanne). 2021;8:667117. doi:10.3389/fmed. 2021.
667117.
24. Chen T, Zhang L, Chen Y, Li S, Xu Y, Wang W, et al. Efficacy
and safety of roxadustat for the treatment of anemia in nondialysis-dependent chronic kidney disease: a systematic review
and meta-analysis. Front Pharmacol. 2022;13:971073.
doi:10.3389/fphar.2022.971073.
25. Haase VH. Hypoxia-inducible factor-prolyl hydroxylase
inhibitors in the treatment of anemia of chronic kidney disease.
Kidney Int Suppl. 2021;11(1):8-25. doi:10.1016/j.kisu.
2020.12.002.
Downloads
Published
Issue
Section
License
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
Journal of Bahria University Medical & Dental College is an open access journal and is licensed under CC BY-NC 4.0. which permits unrestricted non commercial use, distribution and reproduction in any medium, provided the original work is properly cited. To view a copy of this license, visit https://creativecommons.org/licenses/by-nc/4.0
